干扰素β治疗与多发性硬化症患者皮肤并发症相关,德黑兰,2021 - 2

Fakhri Allahyari, Esmat Davoudi-Monfared, Hamideh Molaei, Fateme Shahabi, Davoud Tanbakuchi, Mohsen Shahrivar
{"title":"干扰素β治疗与多发性硬化症患者皮肤并发症相关,德黑兰,2021 - 2","authors":"Fakhri Allahyari, Esmat Davoudi-Monfared, Hamideh Molaei, Fateme Shahabi, Davoud Tanbakuchi, Mohsen Shahrivar","doi":"10.5812/jssc-137862","DOIUrl":null,"url":null,"abstract":"Background: Interferons are generally prescribed in multiple sclerosis (MS) treatment. This study was done to investigate the severity and type of skin side effects of interferon beta (IFNβ) in patients with MS. Methods: This was a cross-sectional descriptive study on the patients with MS taking IFNβ medication referred to Baqiyatullah Hospital in 2021 - 22. The sample size was 322, and the sampling method was census. Data were documented in a checklist, and analyses were performed by SPSS software version 24 at a significance level of 0.05. Result: About 46% of patients had no skin complications. The erythema at the injection site was the commonest skin complication (45.2%). The hair loss severity after treatment had a statistically significant increase than before (P < 0.001). If the severity of the patient's current disease was moderate, the estimated odds of developing the erythema compared to no complication was 2.60 times higher than the patient with mild current severity of the disease (P = 0.003), and if the severity of the current disease was moderate, the estimated odds of developing erythema + eczema than no complications was 7.70 times higher than the patient with the current severity of the mild disease (P = 0.001). Conclusions: The most important skin complications MS patients experience following the use of IFNβ are injection site skin reactions and erythema. Hair loss increased in MS patients after IFNβ treatment. Prospective studies on the procedure of hair loss after treatment with IFNβ in MS patients are recommended.","PeriodicalId":174870,"journal":{"name":"Journal of Skin and Stem Cell","volume":"131 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Skin Complications Associated with Interferon-β Treatment in Patients with Multiple Sclerosis, Tehran in 2021 - 2\",\"authors\":\"Fakhri Allahyari, Esmat Davoudi-Monfared, Hamideh Molaei, Fateme Shahabi, Davoud Tanbakuchi, Mohsen Shahrivar\",\"doi\":\"10.5812/jssc-137862\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Interferons are generally prescribed in multiple sclerosis (MS) treatment. This study was done to investigate the severity and type of skin side effects of interferon beta (IFNβ) in patients with MS. Methods: This was a cross-sectional descriptive study on the patients with MS taking IFNβ medication referred to Baqiyatullah Hospital in 2021 - 22. The sample size was 322, and the sampling method was census. Data were documented in a checklist, and analyses were performed by SPSS software version 24 at a significance level of 0.05. Result: About 46% of patients had no skin complications. The erythema at the injection site was the commonest skin complication (45.2%). The hair loss severity after treatment had a statistically significant increase than before (P < 0.001). If the severity of the patient's current disease was moderate, the estimated odds of developing the erythema compared to no complication was 2.60 times higher than the patient with mild current severity of the disease (P = 0.003), and if the severity of the current disease was moderate, the estimated odds of developing erythema + eczema than no complications was 7.70 times higher than the patient with the current severity of the mild disease (P = 0.001). Conclusions: The most important skin complications MS patients experience following the use of IFNβ are injection site skin reactions and erythema. Hair loss increased in MS patients after IFNβ treatment. Prospective studies on the procedure of hair loss after treatment with IFNβ in MS patients are recommended.\",\"PeriodicalId\":174870,\"journal\":{\"name\":\"Journal of Skin and Stem Cell\",\"volume\":\"131 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Skin and Stem Cell\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/jssc-137862\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Skin and Stem Cell","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/jssc-137862","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:干扰素通常用于多发性硬化症(MS)的治疗。本研究旨在探讨干扰素β (IFNβ)对MS患者皮肤副作用的严重程度和类型。方法:对2021 - 2022年在Baqiyatullah医院转诊的服用IFNβ药物的MS患者进行横断面描述性研究。样本量为322人,抽样方法为人口普查。数据以检查表形式记录,采用SPSS软件版本24进行分析,显著性水平为0.05。结果:约46%的患者无皮肤并发症。注射部位的红斑是最常见的皮肤并发症(45.2%)。治疗后脱发严重程度较治疗前有统计学意义(P < 0.001)。如果患者当前疾病的严重程度为中度,与无并发症的患者相比,估计发生红斑的几率比目前疾病严重程度轻度的患者高2.60倍(P = 0.003),如果当前疾病的严重程度为中度,与无并发症的患者相比,估计发生红斑+湿疹的几率比目前疾病严重程度轻度的患者高7.70倍(P = 0.001)。结论:使用IFNβ后,MS患者最主要的皮肤并发症是注射部位皮肤反应和红斑。IFNβ治疗后,MS患者脱发增加。建议对多发性硬化症患者接受IFNβ治疗后脱发的过程进行前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Skin Complications Associated with Interferon-β Treatment in Patients with Multiple Sclerosis, Tehran in 2021 - 2
Background: Interferons are generally prescribed in multiple sclerosis (MS) treatment. This study was done to investigate the severity and type of skin side effects of interferon beta (IFNβ) in patients with MS. Methods: This was a cross-sectional descriptive study on the patients with MS taking IFNβ medication referred to Baqiyatullah Hospital in 2021 - 22. The sample size was 322, and the sampling method was census. Data were documented in a checklist, and analyses were performed by SPSS software version 24 at a significance level of 0.05. Result: About 46% of patients had no skin complications. The erythema at the injection site was the commonest skin complication (45.2%). The hair loss severity after treatment had a statistically significant increase than before (P < 0.001). If the severity of the patient's current disease was moderate, the estimated odds of developing the erythema compared to no complication was 2.60 times higher than the patient with mild current severity of the disease (P = 0.003), and if the severity of the current disease was moderate, the estimated odds of developing erythema + eczema than no complications was 7.70 times higher than the patient with the current severity of the mild disease (P = 0.001). Conclusions: The most important skin complications MS patients experience following the use of IFNβ are injection site skin reactions and erythema. Hair loss increased in MS patients after IFNβ treatment. Prospective studies on the procedure of hair loss after treatment with IFNβ in MS patients are recommended.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Crisaborole in Atopic Dermatitis An Update on the Etiopathogenesis and Management of Morbihan Disease: A Narrative Review Facial Acne Management and Sebum Reduction via Botulinum Toxin Type A Treatment: A Review The Gender-Specific Dynamics of Charismaphobia in Relation to Body-Esteem and Self-Esteem: Implications for Cosmetic and Psycho-Dermatology Observational Study of the Changes in Skin Thickness Among Children with Atopic Dermatitis Treated with Topical Mometasone Furoate 0.1% Cream
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1